BioLineRx PT Lowered to $7.00 (BLRX)
Analysts at Aegis lowered their price target on shares of BioLineRx (NASDAQ: BLRX) from $11.00 to $7.00 in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the stock.
BioLineRx (NASDAQ: BLRX) traded down 53.02% on Wednesday, hitting $1.7899. BioLineRx has a 52-week low of $2.20 and a 52-week high of $5.10. The stock’s 50-day moving average is currently $3.9. The company’s market cap is $39.5 million.
BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.